SLC5A2 and diabetes mellitus: SGLT2 inhibitors may also improve vascular function by mobilizing bone marrow-derived CD34-positive circulating progenitor cells and restoring the vascular repair system.111 Using a series of experiments in samples from participants with DM and recent myocardial infarction, Hess and colleagues showed that empagliflozin increases circulating provascular progenitor cells and reduces systemic oxidative stress creating a microenvironment that is more permissive to blood vessel regeneration.111 Additional studies are needed to confirm this intriguing hypothesis.